Investor letter spotlight and what it suggests for Globus Medical (GMED)

Meridian Growth Fund recently called out Globus Medical (GMED) as a key contributor in its fourth quarter 2025 investor letter, tying the stock’s outperformance to what it described as improving trends in the company’s core operations.

The fund pointed to a reacceleration in Globus Medical’s spine business to double digit growth, renewed market share gains, and integration progress from prior acquisitions that it said is tracking ahead of expectations.

Globus Medical’s share price has climbed to US$90.68, with a 90 day share price return of 50.16% contrasting with a 1 year total shareholder return of a 2.20% decline. This suggests that recent momentum has strengthened following the integration progress and spine business reacceleration highlighted in the Meridian Growth Fund letter.

If this kind of healthcare growth story has your attention, it could be a good moment to see what else is moving in healthcare stocks.

Globus Medical now trades at US$90.68 with an implied 18% gap to the average analyst price target and an estimated 21% intrinsic discount. The key question is whether this represents a genuine opportunity or if markets are already accounting for future growth.

Most Popular Narrative: 14.8% Undervalued

At $90.68, the most followed narrative on Globus Medical points to a fair value of $106.40, setting up a clear gap between price and modeled worth.

Continued innovation and adoption of robotics, navigation, and minimally invasive procedures, including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and robust product pipeline, position Globus to capitalize on healthcare digitization trends, driving higher ASPs, stronger market differentiation, and improved gross margins over time.

Want to see what sits behind that fair value jump? This narrative leans on steady revenue growth, rising margins and a richer mix from higher value tech. The specific assumptions might surprise you.

**Result: Fair Value of $106.40 (UNDERVALUED)**

However, there are still watchpoints, including slower international progress and ongoing NuVasive and Nevro integration work, that could challenge the upbeat earnings narrative.

Build Your Own Globus Medical Narrative

If you look at the numbers and reach a different conclusion, or just prefer to test your own assumptions, you can build a custom view in a few minutes with Do it your way.

A great starting point for your Globus Medical research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Globus Medical sparked your interest, do not stop here, these screeners can help you spot other opportunities that fit how you like to invest.

• Target growth potential in smaller names by scanning these 3531 penny stocks with strong financials that pair compact size with stronger financial footing.
• Ride the rise of smarter software and automation by checking out these 25 AI penny stocks shaping how AI shows up across real world businesses.
• Zero in on value by reviewing these 868 undervalued stocks based on cash flows where prices currently sit below estimated cash flow based worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.